ArticleNature communications2018
ADAR1-mediated regulation of melanoma invasion.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 51 citations in OpenAlex.
- TMT proteomics reveals that miR-425-5p promotes proliferation and metastasis of malignant melanoma by inhibiting SCARA5.Cancer cell international · 2026Article
- Adenosine-to-inosine RNA editing in cancer: molecular mechanisms and downstream targets.Protein & cell · 2025Review
- ADAR1 enhances tumor proliferation and radioresistance in non-small cell lung cancer by interacting with Rad18.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- ADAR1-regulated miR-142-3p/RIG-I axis suppresses antitumor immunity in nasopharyngeal carcinoma.Non-coding RNA research · 2025Article
- Inosine: biofunctions and the roles in human diseases.Frontiers in endocrinology · 2025Review
- Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics.Cancer metastasis reviews · 2023Review
- miR-30e-5p-mediated FOXD1 promotes cell proliferation by blocking cellular senescence and apoptosis through p21/CDK2/Rb signaling in head and neck carcinoma.Cell death discovery · 2023Article
- ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma.Cancer medicine · 2023Article
- RNA Editing Enzyme ADAR1 Suppresses the Mobility of Cancer Cells via ARPIN.Molecules and cells · 2023Article
- ADAR1 Non-Editing Function in Macrophage Activation and Abdominal Aortic Aneurysm.Circulation research · 2023Article
- Zα domain proteins mediate the immune response.Frontiers in immunology · 2023Review
- The A-to-I editing of KPC1 promotes intrahepatic cholangiocarcinoma by attenuating proteasomal processing of NF-κB1 p105 to p50.Journal of experimental & clinical cancer research : CR · 2022Article
- Glycan Epitope and Integrin Expression Dynamics Characterize Neural Crest Epithelial-to-Mesenchymal Transition (EMT) in Human Pluripotent Stem Cell Differentiation.Stem cell reviews and reports · 2022Article
- Unifying Different Cancer Theories in a Unique Tumour Model: Chronic Inflammation and Deaminases as Meeting Points.International journal of molecular sciences · 2022Review
- ADAR1 and its implications in cancer development and treatment.Trends in genetics : TIG · 2022Review
- The E3 ubiquitin ligase SMURF2 stabilizes RNA editase ADAR1p110 and promotes its adenosine-to-inosine (A-to-I) editing function.Cellular and molecular life sciences : CMLS · 2022Article
- Midlife brain metastases in the United States: Is male at risk?Cancer medicine · 2022Article
- Review
- ADAR1 promotes systemic sclerosisFrontiers in immunology · 2022Article
- ADAR1-Mediated RNA Editing and Its Role in Cancer.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Melanoma cells use different migratory strategies to exit the primary tumor mass and invade surrounding and subsequently distant tissues. We reported previously that ADAR1 expression is downregulated in metastatic melanoma, thereby facilitating proliferation. Here we show that ADAR1 silencing enhances melanoma cell invasiveness and ITGB3 expression. The enhanced invasion is reversed when ITGB3 is blocked with antibodies. Re-expression of wild-type or catalytically inactive ADAR1 establishes this mechanism as independent of RNA editing. We demonstrate that ADAR1 controls ITGB3 expression both at the post-transcriptional and transcriptional levels, via miR-22 and PAX6 transcription factor, respectively. These are proven here as direct regulators of ITGB3 expression. miR-22 expression is controlled by ADAR1 via FOXD1 transcription factor. Clinical relevance is demonstrated in patient-paired progression tissue microarray using immunohistochemistry. The novel ADAR1-dependent and RNA-editing-independent regulation of invasion, mediated by ITGB3, strongly points to a central involvement of ADAR1 in cancer progression and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.